Chimeric Therapeutics Ltd (ASX:CHM) is moving swiftly in the quest to expand its CLTX CAR intellectual property portfolio, with the receipt of a patent grant from India and a notice of allowance from Israel.
The India patent covers certain applications of chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX), including Chimeric’s clinical-stage CAR T asset CHM 1101 and pre-clinical stage CAR NK asset CHM 1301.
“We are delighted to have patent protection granted for CLTX CAR therapies in India and shortly in Israel, as we continue to expand the robust intellectual property portfolio underpinning our CLTX CAR pipeline assets,” Chimeric Therapeutics chief executive officer and managing director Jennifer Chow said.
The India patent has been granted under patent number IN 424963, while the Official Notification Prior to Acceptance from the Israel Patent Office is for application IL 258670.
Chimeric Therapeutics, the only ASX-listed clinical stage cell therapy company, holds the exclusive worldwide licence to develop and commercialise IN 424963, IL 258670, and related patent applications filed in other global territories.
About CHM 1101
CHM 1101 is a first-in-class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma, patients who have a poor prognosis, with limited treatment options and a median survival of less than one year.
CHM 1101 cells uniquely use chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalker scorpion venom, as the tumour-targeting component of the chimeric antigen receptor (CAR).
In pre-clinical models, CHM 1101 CAR T cells have been shown to bind more broadly and specifically to glioblastoma cells than other targeting domains like EGFR, HER-2 or IL-13.
CHM 1101 cells also demonstrated potent anti-tumour activity against glioblastoma, while not exhibiting any off-tumour recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile.
CHM 1101 is being studied in an ongoing phase 1A clinical trial in recurrent/progressive glioblastoma at City of Hope Cancer Centre in California.
Outcomes from the initial two dose levels of the Phase 1A trial have been previously presented and demonstrated patient safety, with a disease stability rate of around 70%.